Hovdenak N
Scand J Gastroenterol Suppl. 1987;130:81-4. doi: 10.3109/00365528709091004.
The effect of loperamide was investigated in a double-blind, placebo-controlled study in 60 patients with irritable bowel syndrome (IBS). Active treatment was given in low dosage (4 mg nocte). The effect of treatment was assessed in clinical subgroups. In a group of patients with painless diarrhoea (n = 16) there was a highly significant improvement in stool frequency and consistency. In a group with alternating bowel habits and abdominal pain (n = 21) there was also a statistically significant improvement in stool frequency and consistency as well as significantly fewer painful days during loperamide treatment. Patients with alternating bowel habits and no pain (n = 12) experienced no symptomatic improvement, and patients with constipation (n = 9) generally felt worse on loperamide. No side effects were encountered. It is concluded that loperamide can be considered an alternative symptomatic treatment in some IBS patients whose main symptoms are painless diarrhoea or alternating bowel habits associated with abdominal pain.
在一项针对60例肠易激综合征（IBS）患者的双盲、安慰剂对照研究中，对洛哌丁胺的疗效进行了调查。采用低剂量（每晚4毫克）进行积极治疗。在临床亚组中评估治疗效果。在一组无痛性腹泻患者（n = 16）中，大便频率和稠度有非常显著的改善。在一组有排便习惯交替和腹痛的患者（n = 21）中，洛哌丁胺治疗期间大便频率和稠度也有统计学上的显著改善，且疼痛天数明显减少。有排便习惯交替但无疼痛的患者（n = 12）症状无改善，便秘患者（n = 9）服用洛哌丁胺后总体感觉更差。未发现副作用。得出的结论是，对于一些主要症状为无痛性腹泻或与腹痛相关的排便习惯交替的IBS患者，洛哌丁胺可被视为一种替代的对症治疗药物。
